Simcere Entered into an Exclusive License Agreement with Almirall for SIM0278 to Treat Autoimmune Diseases
Shots:
- Simcere to receive a $15M up front, ~$492M in development, commercial & sales milestones in multiple indications along with royalties
- Almirall to get an exclusive right to develop & commercialize SIM0278 for all indications outside of the Greater China region (Mainland China, Hong Kong, Macau & Taiwan). Simcere holds all rights within Greater China
- SIM0278 is an interleukin 2 mutant fusion protein (IL-2 mu-Fc) that uses the protein engineering platform of Simcere to stimulate regulatory T cells & is designed to treat immunological diseases. In multiple preclinical disease models, SIM0278 showed a better PK profile & selective activation of Treg cells with no activation of effector T cells or NK cells to restore immunological balance
Ref: PRNewswire | Image: Simcere
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
